Hsin joined OMass in July 2018 and has been serving as SVP, Finance and Operations. Prior to joining OMass, she spent 16 years at GSK in a variety of leadership roles, including heading Finance, Strategy and Operations for GSK’s Rare Diseases Unit. Hsin completed her BA (Hons) in Biological Sciences and D.Phil. in Genetics and Immunology at the University of Oxford, and qualified as a Chartered Accountant at PwC. She currently serves on the Board of the Cell and Gene Therapy Catapult (CGT Catapult).
Jon joined OMass in July 2022 as VP, Head of Medicinal Chemistry. Jon has over 20 years’ experience in drug discovery across a variety of therapeutic areas, including oncology, CNS and metabolic disorders and a range of therapeutic modalities. Jon joined OMass from Nanna Therapeutics, where he was Head of Chemistry, leading a portfolio of mitochondrial targeted programmes to treat rare diseases. Prior to that, he was Director of Chemistry at Azeria Therapeutics, a company he helped spin-out from the University of Cambridge. Previous roles include Senior Group Leader at Cancer Research Technology and Senior Scientist and Project Lead at Spirogen, where he established and led its antibody drug conjugate programme. He started his medicinal chemistry career at Vernalis as a Senior Scientist working on a variety of GPCR targets. He has a Ph.D. in Organic Chemistry obtained from the University of Loughborough.
Hsin Loke, Chief Operating Officer and Senior Vice President, Finance at OMass Therapeutics, said:
I am delighted to take on the role of COO at OMass, further supporting the Company’s strategic goals. Selecting a clinical candidate for our MC2 programme is a key milestone for our team and a testament to our focus and dedication. I look forward to helping drive more advancements in our pipeline of small molecule therapeutics targeting rare diseases and immunological conditions.
Jon Roffey, Senior Vice President, Discovery and Non-Clinical at OMass Therapeutics, added:
Our OdyssION™ platform is revolutionising how we interrogate the fundamental interactions driving life, allowing us to develop differentiated small molecules against complex-bound and membrane targets. As SVP, Discovery and Non-Clinical, I am excited to continue using my drug discovery expertise to develop innovative treatments for rare immunological and genetic diseases with high unmet patient need.
-ENDS-
For further information, please contact:
| OMass Therapeutics | ICR Healthcare |
| Rosamond Deegan, Chief Executive Officer
Phone: +44 (0) 1235 527589 Email: ros.deegan@omass.com
|
Sue Charles / Sukaina Virji / Kumail Waljee
Phone: +44 (0)20 3709 5700 Email: omass@icrhealthcare.com
|
About OMass Therapeutics
OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes.
OdyssION™, OMass’ unique drug discovery platform, comprises next-generation native mass spectrometry with novel biochemistry techniques and custom chemistry to interrogate not just a drug target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. This unique approach results in cell-system fidelity with cell-free precision.
OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead programme is a best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of Congenital Adrenal Hyperplasia (CAH) and Cushing’s Syndrome. The focus of the program has been to increase receptor residency time to make OMass’ antagonists resistant to competition by the endogenous ligand, thereby avoiding loss of efficacy in the face of rising adrenocorticotropic hormone (ACTH) levels due to reductions in glucocorticoid supplementation for CAH or progression of Cushing’s Syndrome.
Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.
To learn more, please visit www.omass.com.